Outside Biogen headquarters (Adam Glanzman/Bloomberg via Getty Images)
In another accelerated approval quest, Biogen will send its ALS drug to the FDA despite inconclusive data
The controversial Aduhelm approval continues to reverberate in Biogen’s development strategy, as the FDA will review another CNS drug from the biotech despite clinical trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
